First Daily Weight Loss Pill Approved by FDA
Millions of Americans now have a more convenient option for weight loss treatment. The FDA just approved Foundayo, a once-daily pill that ships Monday and costs as little as $25 a month with insurance.
The FDA approved the first widely accessible weight loss pill that could make treatment easier for millions of people looking for an alternative to weekly injections.
Eli Lilly's Foundayo starts shipping Monday from the company's direct platform and will arrive at pharmacies shortly after. People with insurance can pay just $25 monthly with a coupon, while those paying out of pocket will spend $149 to $349 depending on dosage.
The pill doesn't require the weekly injections that current treatments like Zepbound demand. It works at any time of day without food restrictions, making it simpler to fit into daily routines than competing options that require early morning timing on an empty stomach.
"It's more accessible, it's easier to fit into your daily routine," said Eli Lilly CEO Dave Ricks. The company invested more than $55 billion in manufacturing since 2020 to prepare for global distribution.
Foundayo produces about 12.4% average weight loss in patients who stay on treatment. While that's less dramatic than injectable options showing over 20% weight loss, doctors say having more choices helps more people find treatment that works for their lifestyle.
Why This Inspires
The pill format solves a manufacturing challenge that could help millions worldwide access treatment. Unlike injectable medications that require complex production and cold storage, Foundayo can be scaled quickly and shipped globally without special handling.
Lilly expects approval in more than 40 countries over the next year. The company sees the pill as perfect for people who reach their goal weight with injections and want easier maintenance, or those who simply prefer taking a daily pill.
Early evidence suggests pills are expanding the market rather than just converting existing patients. That means more people are getting help who might have avoided injections altogether.
Price remains the biggest factor in patient decisions, and Foundayo matches competitor pricing at $149 for the lowest dose. For the first time, convenience and accessibility won't come at a premium.
More options mean more people can find a path that works for them.
Based on reporting by Google: new treatment approved
This story was written by BrightWire based on verified news reports.
Spread the positivity!
Share this good news with someone who needs it
